Targeted Therapy in Biliary Tract Cancers

Current Treatment Options in Oncology

Volumn 16, Issue 10, 2015, Pages

  Merla, Amartej ^a   Liu, Kenneth G ^a   Rajdev, Lakshmi ^a  

^a MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

Biliary tract cancer; EGFR; Targeted therapy; Trial; VEGF

Indexed keywords

AFATINIB; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BINIMETINIB; CAPECITABINE; CEDIRANIB; CETUXIMAB; CISPLATIN; ERLOTINIB; ETOPOSIDE; EVEROLIMUS; FLUOROURACIL; GEMCITABINE; INFIGRATINIB; IRINOTECAN; LAPATINIB; N (6,7 DIHYDRO 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL) 2,2 DIMETHYL N' (2,2,3,3,3 PENTAFLUOROPROPYL)PROPANEDIAMIDE; OXALIPLATIN; PANITUMUMAB; PAZOPANIB; PLACEBO; PONATINIB; REGORAFENIB; SELUMETINIB; SORAFENIB; SUNITINIB; TRAMETINIB; UNINDEXED DRUG; VANDETANIB; VISMODEGIB;

ALCOHOLISM; BILE DUCT CYST; BILIARY TRACT CANCER; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER SURVIVAL; CELL CYCLE REGULATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; DIABETES MELLITUS; DRUG RESPONSE; FASCIOLA HEPATICA; GALLSTONE; GENE FREQUENCY; GENE MUTATION; HEPATITIS B; HEPATITIS C; HUMAN; INFLAMMATORY BOWEL DISEASE; LIGAND BINDING; LYMPH NODE METASTASIS; MICROSATELLITE INSTABILITY; OBESITY; OVERALL SURVIVAL; PARASITOSIS; PERSONALIZED MEDICINE; POPULATION RESEARCH; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN DOMAIN; PROTEIN TARGETING; RECURRENCE FREE SURVIVAL; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; SMOKING; TREATMENT DURATION; BILIARY TRACT NEOPLASMS; CANCER STAGING; DISEASE FREE SURVIVAL; MOLECULARLY TARGETED THERAPY; PATHOLOGY; TRENDS;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILIARY TRACT NEOPLASMS; DISEASE-FREE SURVIVAL; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; PROGNOSIS;

EID: 84939219427     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-015-0366-0     Document Type: Review

References (107)

1. de Groen PC et al. Biliary tract cancers. N Engl J Med. 1999;341(18):1368–78.
2. Klatskin G. Adenocarcinoma of the hepatic duct at its bifurcation within the porta hepatis. An unusual tumor with distinctive clinical and pathological features. Am J Med. 1965;38:241–56.
3. Olnes MJ, Erlich R. A review and update on cholangiocarcinoma. Oncology. 2004;66(3):167–79.
4. Lazcano-Ponce EC et al. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin. 2001;51(6):349–64.
5. Castro FA et al. Biliary tract cancer incidence in the United States—demographic and temporal variations by anatomic site. Int J Cancer. 2013;133(7):1664–71.
6. Randi G et al. Epidemiology of biliary tract cancers: an update. Ann Oncol. 2009;20(1):146–59.
7. Andia KM, Gederlini GA, Ferreccio RC. Gallbladder cancer: trend and risk distribution in Chile. Rev Med Chil. 2006;134(5):565–74.
8. Altekruse SF et al. Geographic variation of intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and hepatocellular carcinoma in the United States. PLoS One. 2015;10(3), e0120574.
9. Shaib YH et al. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol. 2004;40(3):472–7.
10. Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis. 2004;24(2):115–25.
11. Grainge MJ et al. The antecedents of biliary cancer: a primary care case-control study in the United Kingdom. Br J Cancer. 2009;100(1):178–80.
12. Parsi MA. Obesity and cholangiocarcinoma. World J Gastroenterol. 2013;19(4):457–62.
13. Larsson SC, Wolk A. Obesity and the risk of gallbladder cancer: a meta-analysis. Br J Cancer. 2007;96(9):1457–61.
14. Li M et al. Hepatitis B virus infection increases the risk of cholangiocarcinoma: a meta-analysis and systematic review. J Gastroenterol Hepatol. 2012;27(10):1561–8.
15. Welzel TM et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol. 2007;5(10):1221–8.
16. Jain K et al. Sequential occurrence of preneoplastic lesions and accumulation of loss of heterozygosity in patients with gallbladder stones suggest causal association with gallbladder cancer. Ann Surg. 2014;260(6):1073–80.
17. Roa I et al. Preneoplastic lesions in gallbladder cancer. J Surg Oncol. 2006;93(8):615–23.
18. Trivedi V et al. Gallbladder cancer: adenoma-carcinoma or dysplasia-carcinoma sequence? Gastroenterol Hepatol (N Y). 2008;4(10):735–7.
19. Mayo SC et al. National trends in the management and survival of surgically managed gallbladder adenocarcinoma over 15 years: a population-based analysis. J Gastrointest Surg. 2010;14(10):1578–91.
20. Ribero D et al. Surgical approach for long-term survival of patients with intrahepatic cholangiocarcinoma: a multi-institutional analysis of 434 patients. Arch Surg. 2012;147(12):1107–13.
21. Farges O et al. Influence of surgical margins on outcome in patients with intrahepatic cholangiocarcinoma: a multicenter study by the AFC-IHCC-2009 study group. Ann Surg. 2011;254(5):824–29. discussion 830.
22. Silva MA et al. Surgery for hilar cholangiocarcinoma; a 10 year experience of a tertiary referral centre in the UK. Eur J Surg Oncol. 2005;31(5):533–9.
23. Valle J et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–81.
24. Darwish Murad S et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology. 2012;143(1):88–98. e3; quiz e14.
25. Agrawal S et al. Outcomes of adjuvant chemoradiation and predictors of survival after extended cholecystectomy in gall bladder carcinoma: a single institution experience from an endemic region. J Gastrointest Cancer. 2015;46(1):48–53.
26. Groot Koerkamp B, Fong Y. Outcomes in biliary malignancy. J Surg Oncol. 2014;110(5):585–91.
27. Glimelius B et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol. 1996;7(6):593–600.
28. Valle JW et al. Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study—the UK ABC-01 Study. Br J Cancer. 2009;101(4):621–7.
29. Furuse J, Okusaka T, Miyazaki M, et al., A randomized study of gemcitabine/cisplatin versus single-agent gemcitabine in patients with biliary cancer. J Clin Oncol, 2009. 27(15_suppl: abstr #4579).
30. Yang R et al. Efficacy of gemcitabine plus platinum agents for biliary tract cancers: a meta-analysis. Anti-Cancer Drugs. 2013;24(8):871–7.
31. Pignochino Y et al. Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. BMC Cancer. 2010;10:631.
32. Chang YT et al. Clinicopathological and prognostic significances of EGFR, KRAS and BRAF mutations in biliary tract carcinomas in Taiwan. J Gastroenterol Hepatol. 2014;29(5):1119–25.
33. Ross JS, et al. Comprehensive genomic profiling of biliary tract cancers to reveal tumor-specific differences and genomic alterations. J Clin Oncol, 2015. 33(3_suppl: abstr #231). This reference presented data on comprehensive genomic profiling in BTC, including the presence/absence of genetic mutations and their relative frequencies in the subtypes of BTC.
34. Li M et al. Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway. Nat Genet. 2014;46(8):872–6.
35. Kumari N et al. Mutation profiling in gallbladder cancer in Indian population. Indian J Pathol Microbiol. 2014;57(1):9–12.
36. Wang SN et al. Aberrant p53 expression and the development of gallbladder carcinoma and adenoma. Kaohsiung J Med Sci. 2006;22(2):53–9.
37. Saetta AA et al. High-level microsatellite instability is not involved in gallbladder carcinogenesis. Exp Mol Pathol. 2006;80(1):67–71.
38. Normanno N et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006;366(1):2–16.
39. Yoshikawa D et al. Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer. 2008;98(2):418–25.
40. Kaufman M et al. EGFR expression in gallbladder carcinoma in North America. Int J Med Sci. 2008;5(5):285–91.
41. Zhou YM et al. Significance of expression of epidermal growth factor (EGF) and its receptor (EGFR) in chronic cholecystitis and gallbladder carcinoma. Ai Zheng. 2003;22(3):262–5.
42. Philip PA et al. Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol. 2006;24(19):3069–74.
43. Lubner SJ et al. Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II consortium study. J Clin Oncol. 2010;28(21):3491–7.
44. Lee J et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2012;13(2):181–8. This is the only published phase III trial investigating the use of a targeted agent (erlotinib) in BTC, looking at erlotinib in combination with gemcitabine and oxaliplatin.
45. Gruenberger B et al. Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study. Lancet Oncol. 2010;11(12):1142–8.
46. Malka D et al. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. Lancet Oncol. 2014;15(8):819–28. A randomized phase II trial evaluating the role of cetuximab in combination with gemcitabine/oxaliplatin in advanced BTC.
47. Chen JS et al. A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer. Ann Oncol. 2015;26(5):943–9. A randomized phase II trial evaluating the role of cetuximab in combination with gemcitabine/oxaliplatin in advanced BTC.
48. Rubovszky G et al. Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: a phase 2 study. Eur J Cancer. 2013;49(18):3806–12.
49. Hezel AF et al. Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer. Br J Cancer. 2014;111(3):430–6.
50. Leone F, et al. A phase II, open-label, randomized clinical trial of panitumumab plus gemcitabine and oxaliplatin (GEMOX) versus GEMOX alone as first-line treatment in advanced biliary tract cancer: the Vecti-BIL study. J Clin Oncol, 2015. 33(3_suppl: abstr #281).
51. Jensen LH et al. Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer. Ann Oncol. 2012;23(9):2341–6.
52. Sohal DP et al. A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma. Ann Oncol. 2013;24(12):3061–5.
53. Menard S et al. Role of HER2/neu in tumor progression and therapy. Cell Mol Life Sci. 2004;61(23):2965–78.
54. Kiguchi K et al. Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma. Cancer Res. 2001;61(19):6971–6.
55. Javle M et al. HER2/neu-directed therapy for biliary tract cancer. J Hematol Oncol. 2015;8:58.
56. Ramanathan RK et al. A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol. 2009;64(4):777–83.
57. Goel HL, Mercurio AM. VEGF targets the tumour cell. Nat Rev Cancer. 2013;13(12):871–82.
58. Quan ZW et al. Association of p53, p16, and vascular endothelial growth factor protein expressions with the prognosis and metastasis of gallbladder cancer. J Am Coll Surg. 2001;193(4):380–3.
59. Zhu AX et al. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol. 2010;11(1):48–54.
60. Iyer RV, et al. Gemcitabine (G), capecitabine (C) and bevacizumab (BV) in patients with advanced biliary cancers (ABC): final results of a multicenter phase II study. J Clin Oncol, 2015. 33(15_suppl: abstr #4078).
61. Wedge SR et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 2005;65(10):4389–400.
62. Benckert C et al. Transforming growth factor beta 1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells. Cancer Res. 2003;63(5):1083–92.
63. Valle J, et al. ABC-03: a randomized phase II trial of cediranib (AZD2171) or placebo in combination with cisplatin/gemcitabine (CisGem) chemotherapy for patients (pts) with advanced biliary tract cancer (ABC). J Clin Oncol, 2014. 32(15_suppl: abstr #4002). A randomized phase II trial evaluating the role of cediranib in combination with gemcitabine/cisplatin in advanced BTC.
64. ClinicalTrials.gov (NCT01229111), Cediranib maleate and combination chemotherapy in treating patients with advanced biliary cancers.
65. Keating GM, Santoro A. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs. 2009;69(2):223–40.
66. Bengala C et al. Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial. Br J Cancer. 2010;102(1):68–72.
67. El-Khoueiry AB et al. SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma. Investig New Drugs. 2012;30(4):1646–51.
68. Moehler M et al. Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme. Eur J Cancer. 2014;50(18):3125–35.
69. Krege S et al. Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO-AB 31/05). BJU Int. 2014;113(3):429–36.
70. Lee JK et al. A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas. Br J Cancer. 2013;109(4):915–9.
71. Kim A, Balis FM, Widemann BC. Sorafenib and sunitinib. Oncologist. 2009;14(8):800–5.
72. Yi JH et al. A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: a multicentre, multinational study. Eur J Cancer. 2012;48(2):196–201.
73. Santoro A et al. A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study. Ann Oncol. 2015;26(3):542–7. A randomized phase II trial evaluating the role of vandetanib monotherapy or in combination with gemcitabine.
74. Wellbrock C, Karasarides M, Marais R. The RAF proteins take centre stage. Nat Rev Mol Cell Biol. 2004;5(11):875–85.
75. Khokhlatchev AV et al. Phosphorylation of the MAP kinase ERK2 promotes its homodimerization and nuclear translocation. Cell. 1998;93(4):605–15.
76. Solit DB et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature. 2006;439(7074):358–62.
77. Tannapfel A et al. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut. 2003;52(5):706–12.
78. Bekaii-Saab T et al. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol. 2011;29(17):2357–63.
79. Finn RS, et al. A phase I study of MEK inhibitor MEK162 (ARRY-438162) in patients with biliary tract cancer. J Clin Oncol, 2012. 30(4_suppl: abstr #220).
80. Lowery MA, et al. A phase I trial of binimetinib in combination with gemcitabine (G) and cisplatin (C) patients (pts) with untreated advanced biliary cancer (ABC). J Clin Oncol, 2015. 33(15_suppl: abstr #e15125).
81. Deshpande V et al. Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma. BMC Cancer. 2011;11:60.
82. Lunardi A et al. Role of aberrant PI3K pathway activation in gallbladder tumorigenesis. Oncotarget. 2014;5(4):894–900.
83. Lebwohl D et al. Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases. Ann N Y Acad Sci. 2013;1291:14–32.
84. Buzzoni R et al. Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study. Ann Oncol. 2014;25(8):1597–603.
85. Yeung YH, et al. Phase II study of everolimus monotherapy as first-line treatment in advanced biliary tract cancer: RADichol. J Clin Oncol, 2014. 32(15_suppl: abstr #4101).
86. Chen MH et al. Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma. Oncotarget. 2014;5(9):2372–89.
87. Varjosalo M, Taipale J. Hedgehog: functions and mechanisms. Genes Dev. 2008;22(18):2454–72.
88. Gailani MR et al. The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. Nat Genet. 1996;14(1):78–81.
89. ClinicalTrials.gov (NCT01546519). A study of the Hedgehog pathway inhibitor vismodegib in patients with advanced solid malignancies including hepatocellular carcinoma with varying degrees of renal or hepatic function. clinical trials.gov.
90. Jinawath A et al. Dual blockade of the Hedgehog and ERK1/2 pathways coordinately decreases proliferation and survival of cholangiocarcinoma cells. J Cancer Res Clin Oncol. 2007;133(4):271–8.
91. South AP, Cho RJ, Aster JC. The double-edged sword of Notch signaling in cancer. Semin Cell Dev Biol. 2012;23(4):458–64.
92. Lobry C et al. Notch signaling: switching an oncogene to a tumor suppressor. Blood. 2014;123(16):2451–9.
93. Yoon HA et al. Clinicopathological significance of altered Notch signaling in extrahepatic cholangiocarcinoma and gallbladder carcinoma. World J Gastroenterol. 2011;17(35):4023–30.
94. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol. 2007;25:267–96.
95. Yamamoto K et al. MUC1 peptide vaccination in patients with advanced pancreas or biliary tract cancer. Anticancer Res. 2005;25(5):3575–9.
96. Lepisto AJ et al. A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. Cancer Ther. 2008;6(B):955–64.
97. Shimizu K et al. Clinical utilization of postoperative dendritic cell vaccine plus activated T-cell transfer in patients with intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Sci. 2012;19(2):171–8.
98. Churi CR et al. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS One. 2014;9(12), e115383.
99. Haga H, Patel T. Molecular diagnosis of intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Sci. 2015;22(2):114–23.
100. Arai Y et al. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology. 2014;59(4):1427–34.
101. ClinicalTrials.gov (NCT02150967). A phase ii, single arm study of BGJ398 in patients with advanced cholangiocarcinoma.
102. Borger DR et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist. 2012;17(1):72–9. Presence of IDH mutations identifies a new target for therapy in IHCC.
103. ClinicalTrials.gov (NCT02481154). Study of orally administered AG-881 in patients with advanced solid tumors, including gliomas, with an IDH1 and/or IDH2 mutation.
104. ClinicalTrials.gov (NCT02073994). Study of orally administered AG-120 in subjects with advanced solid tumors, including glioma, with an IDH1 mutation.
105. Ocean AJ et al. Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol. 2011;68(2):379–88.
106. Zhang LQ et al. Potential therapeutic targets for the primary gallbladder carcinoma: estrogen receptors. Asian Pac J Cancer Prev. 2013;14(4):2185–90.
107. Weinstein JN et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet. 2013;45(10):1113–20.